23 Mm Portico(TM) Transcatheter Aortic Heart Valve - Image Courtesy Of St. Jude Medical.

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it has received European CE Mark approval for its 23 mm Portico™ Transcatheter Aortic Heart Valve and Transfemoral Delivery System. Designed for patients with severe aortic stenosis who are considered to be inoperable or high risk for conventional open-heart valve replacement surgery, the Portico valve is implanted through a small incision in the femoral artery (the main artery of the leg). The procedure uses a catheter placed percutaneously (through the skin) to deliver and position the valve in the heart and occurs while the heart continues to beat. This avoids the need to place the patient on cardiopulmonary bypass, a process in which a machine takes over heart and lung function during surgery.
23 mm Portico(TM) Transcatheter Aortic Heart Valve - Image courtesy of St. Jude Medical.

23 mm Portico(TM) Transcatheter Aortic Heart Valve - Image courtesy of St. Jude Medical.

The Portico device is the only approved transcatheter valve that can be completely resheathed (the process of bringing the valve back into the delivery catheter), repositioned at the implant site or retrieved before it is released from the delivery system. The valve was designed in collaboration with leading physicians to address limitations of current-generation devices by improving control and accuracy in positioning and placement of the valve, minimizing paravalvular leak (a common complication with first-generation transcatheter valves) and potentially reducing the need for the implantation of a permanent pacemaker after the procedure.

“The ability to completely resheath, reposition or retrieve the Portico valve is an important improvement over previous-generation transcatheter valves,” said Dr. Ganesh Manoharan of Royal Victoria Hospital in Belfast, U.K. “This is particularly helpful in ensuring accurate placement of the valve and minimizing complications for this high risk population.”

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical